Clinical Trials · NCT04869371
Androgen Deprivation Therapy Combined With Docetaxel for High Risk Prostate Cancer
- Phase
- Phase 2
- Recruitment status
- Unknown
- Sponsor
- Hongqian Guo
- Enrollment
- 75
- Start date
- Dec 2018
- Locations
- 1 site, China
- Primary endpoint
- Pathologic Complete Response Rate